236 related articles for article (PubMed ID: 33154056)
1. Expanding the upper age limit for cervical cancer screening: a protocol for a nationwide non-randomised intervention study.
Tranberg M; Petersen LK; Elfström KM; Hammer A; Blaakær J; Bennetsen MH; Jensen JS; Andersen B
BMJ Open; 2020 Nov; 10(11):e039636. PubMed ID: 33154056
[TBL] [Abstract][Full Text] [Related]
2. Value of a catch-up HPV test in women aged 65 and above: A Danish population-based nonrandomized intervention study.
Tranberg M; Petersen LK; Hammer A; Elfström M; Blaakær J; Jørgensen SF; Bennetsen MH; Jensen JS; Andersen B
PLoS Med; 2023 Jul; 20(7):e1004253. PubMed ID: 37410699
[TBL] [Abstract][Full Text] [Related]
3. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
[TBL] [Abstract][Full Text] [Related]
4. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program.
Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B
BMC Cancer; 2016 Nov; 16(1):835. PubMed ID: 27809810
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
8. Study protocol of the ACCESS trial: a randomised trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection.
Fujita M; Shimazu M; Nagashima K; Suzuki M; Tauchi I; Sakuma M; Yamamoto S; Shozu M; Hanaoka H; Tsuruoka N; Kasai T; Hata A
BMJ Open; 2022 Feb; 12(2):e049803. PubMed ID: 35115348
[TBL] [Abstract][Full Text] [Related]
9. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two invitation-based methods for human papillomavirus (HPV) self-sampling with usual care among un- and under-screened Māori, Pacific and Asian women: study protocol for a randomised controlled community trial to examine the effect of self-sampling on participation in cervical-cancer screening.
Brewer N; Bartholomew K; Maxwell A; Grant J; McPherson G; Wihongi H; Bromhead C; Scott N; Crengle S; Cunningham C; Douwes J; Potter JD
BMC Cancer; 2019 Dec; 19(1):1198. PubMed ID: 31815615
[TBL] [Abstract][Full Text] [Related]
11. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
[TBL] [Abstract][Full Text] [Related]
12. Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.
Tranberg M; Jensen JS; Bech BH; Andersen B
BMC Infect Dis; 2020 Dec; 20(1):926. PubMed ID: 33276740
[TBL] [Abstract][Full Text] [Related]
13. CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women.
Morisada T; Teramoto K; Takano H; Sakamoto I; Nishio H; Iwata T; Hashi A; Katoh R; Okamoto A; Sasaki H; Nakatani E; Teramukai S; Aoki D
Cancer Epidemiol; 2017 Oct; 50(Pt A):60-67. PubMed ID: 28818742
[TBL] [Abstract][Full Text] [Related]
14. Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial.
Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B
BMC Cancer; 2018 Mar; 18(1):273. PubMed ID: 29523108
[TBL] [Abstract][Full Text] [Related]
15. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
16. Screening test accuracy to improve detection of precancerous lesions of the cervix in women living with HIV: a study protocol.
Taghavi K; Moono M; Mwanahamuntu M; Basu P; Limacher A; Tembo T; Kapesa H; Hamusonde K; Asangbeh S; Sznitman R; Low N; Manasyan A; Bohlius J
BMJ Open; 2020 Dec; 10(12):e037955. PubMed ID: 33371015
[TBL] [Abstract][Full Text] [Related]
17. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
18. Community-randomised controlled trial embedded in the Anishinaabek Cervical Cancer Screening Study: human papillomavirus self-sampling versus Papanicolaou cytology.
Zehbe I; Jackson R; Wood B; Weaver B; Escott N; Severini A; Krajden M; Bishop L; Morrisseau K; Ogilvie G; Burchell AN; Little J
BMJ Open; 2016 Oct; 6(10):e011754. PubMed ID: 27855089
[TBL] [Abstract][Full Text] [Related]
19. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
20. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
